TG Therapeutics Inc (TGTX)

11.45
NASDAQ : Health Care
Prev Close 11.45
Day Low/High 0.00 / 0.00
52 Wk Low/High 4.10 / 15.05
Avg Volume 2.53M
Exchange NASDAQ
Shares Outstanding 66.78M
Market Cap 757.90M
EPS -1.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

TG Therapeutics, Inc. Announces Clinical Data Presentations At The Upcoming 22nd European Hematology Association Annual Congress

TG Therapeutics, Inc. Announces Clinical Data Presentations At The Upcoming 22nd European Hematology Association Annual Congress

Presentations highlight triple combination therapies with the combination of TG-1101 and TGR-1202 as the backbone

TG Therapeutics, Inc. Recaps Clinical Data Presentations At The Upcoming 53rd Annual Meeting Of The American Society Of Clinical Oncology

TG Therapeutics, Inc. Recaps Clinical Data Presentations At The Upcoming 53rd Annual Meeting Of The American Society Of Clinical Oncology

Positive results from the GENUINE Phase 3 study to be featured in an oral presentation

TG Therapeutics, Inc. Provides Business Update And Reports First Quarter 2017 Financial Results

TG Therapeutics, Inc. Provides Business Update And Reports First Quarter 2017 Financial Results

Investor Conference Call to be Held Today, Friday, May 5, 2017 at 8:30am ET   

TG Therapeutics, Inc. To Host Conference Call On First Quarter 2017 Financial Results And Business Update

TG Therapeutics, Inc. To Host Conference Call On First Quarter 2017 Financial Results And Business Update

Investor Conference Call to be held Friday, May 5, 2017 at 8:30am ET  

Short Interest Makes 12% Move For TGTX

Short Interest Makes 12% Move For TGTX

The most recent short interest data has been released for the 04/13/2017 settlement date, which shows a 1,258,062 share increase in total short interest for TG Therapeutics Inc , to 11,701,533, an increase of 12.05% since 03/31/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Don't Be Surprised If Dip Buyers Jump In on Any Pullback

Don't Be Surprised If Dip Buyers Jump In on Any Pullback

We'll see what happens in the way of reaction to Trump's tax policy this afternoon, but if we sell off I'm likely going to be a buyer.

Desire to Add Exposure Leads Indices Higher

Desire to Add Exposure Leads Indices Higher

The fact that many traders weren't well-positioned for Monday's move up is helping to create one-way action this morning.

If You Don't Buy These 5 Stocks Before Their Looming Breakout, It's Your Loss

If You Don't Buy These 5 Stocks Before Their Looming Breakout, It's Your Loss

Here's how to potentially rake in some fat profits off a number of hot breakout setups.

TG Therapeutics, Inc. Announces Clinical Data Presentations At The Upcoming 53rd Annual Meeting Of The American Society Of Clinical Oncology

TG Therapeutics, Inc. Announces Clinical Data Presentations At The Upcoming 53rd Annual Meeting Of The American Society Of Clinical Oncology

Positive results from the GENUINE Phase 3 study to be featured in an oral presentation

TG Therapeutics Stock Sees Short Interest Increase 21%

TG Therapeutics Stock Sees Short Interest Increase 21%

The most recent short interest data has been released for the 03/31/2017 settlement date, which shows a 1,802,705 share increase in total short interest for TG Therapeutics Inc , to 10,443,471, an increase of 20.86% since 03/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Twilio, HubSpot, TG Therapeutics, Under Armour: 'Mad Money' Lightning Round

Twilio, HubSpot, TG Therapeutics, Under Armour: 'Mad Money' Lightning Round

Jim Cramer is bullish on Twilio, HubSpot and Cemex; he's bearish on Suburban Propane Partners.

Don't Be Fooled by This Retail Relief Rally: Cramer's 'Mad Money' Recap (Thursday 4/6/17)

Don't Be Fooled by This Retail Relief Rally: Cramer's 'Mad Money' Recap (Thursday 4/6/17)

No, people aren't suddenly deciding they want to go back to shopping at the mall, says Jim Cramer.

Commit To Buy TG Therapeutics At $10, Earn 29.1% Annualized Using Options

Commit To Buy TG Therapeutics At $10, Earn 29.1% Annualized Using Options

Investors eyeing a purchase of TG Therapeutics Inc shares, but cautious about paying the going market price of $11.43/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the August put at the $10 strike, which has a bid at the time of this writing of $1.15.

TG Therapeutics, Inc. To Present At The 27th Annual Oppenheimer Healthcare Conference

TG Therapeutics, Inc. To Present At The 27th Annual Oppenheimer Healthcare Conference

Presentation Scheduled for Tuesday, March 21, 2017 at 3:20pm ET

TG Therapeutics, Inc. To Present At The 29th Annual ROTH Conference

TG Therapeutics, Inc. To Present At The 29th Annual ROTH Conference

Presentation Scheduled for Tuesday, March 14, 2017 at 3:00pm PT

Biotech Stock Mailbag: Puma's Rebound Explained, TG Therapeutics Approval Debate, Aurinia Next Steps

Biotech Stock Mailbag: Puma's Rebound Explained, TG Therapeutics Approval Debate, Aurinia Next Steps

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

TG Therapeutics, Inc. To Host Conference Call On Fourth Quarter And Year-End 2016 Financial Results And Business Update

TG Therapeutics, Inc. To Host Conference Call On Fourth Quarter And Year-End 2016 Financial Results And Business Update

Investor Conference Call to be held Friday, March 10, 2017 at 8:30am ET

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Nine biotech and drug companies want FDA approval, but need changed standards to get it.

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

Treehouse Foods, Arconic, Kinder Morgan, Chesapeake Energy: 'Mad Money' Lightning Round

Treehouse Foods, Arconic, Kinder Morgan, Chesapeake Energy: 'Mad Money' Lightning Round

Jim Cramer is bullish on Arconic, Treehouse Foods, Magellan Midstream Partners.